Article Information
History
- January 28, 2023.
Article Versions
- You are currently viewing Version 1 of this article (January 28, 2023 - 14:06).
- Version 2 (August 3, 2023 - 17:18).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Lan Jiang1,
- Ge Liu2,
- Annette Oeser1,
- Andrea Ihegword1,
- Alyson L. Dickson1,3,
- Laura L. Daniel4,
- Adriana M Hung5,6,
- Nancy J. Cox7,
- Cecilia P. Chung4,
- Wei-Qi Wei2,
- C. Michael Stein1,8 and
- QiPing Feng1,7,*
- 1Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
- 2Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN
- 3Division of Rheumatology and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
- 4Division of Rheumatology, Department of Medicine, University of Miami and Miami VA hospital, Miami, FL
- 5Tennessee Valley Healthcare System, Nashville Campus, Nashville, TN
- 6Division of Nephrology & Hypertension, Vanderbilt University Medical Center, Nashville, TN
- 7Vanderbilt Genetics Institute, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
- 8Department of Pharmacology, Vanderbilt University, Nashville, TN
- ↵*Corresponding Author: QiPing Feng, PhD, 536 Robinson Research Building, Vanderbilt University Medical Center, 2222 Pierce Ave., Nashville, TN 37232, USA (Tel:615-936-3551, qiping.feng{at}vumc.org)
Posted January 28, 2023.
Association between APOL1 risk variants and progression from infection to sepsis
